Bayer announced a collaboration agreement, including a joint steering committee, with the University of Pittsburgh focused on advanced research for heart, lung and blood disease Tuesday.
The collaboration incorporates research, drug development and data analysis and will also include a separate clinical trial in sickle cell disease, according to a statement from Whippany-based Bayer.
“Bayer is proud to partner with the University of Pittsburgh, bringing together their renowned scientists in partnership with Bayer’s clinical disease experts and in-depth expertise in delivering new therapies to patients,” said Dario Mirski, senior vice president and head of medical affairs for the Americas at Bayer. “This partnership reflects continued investment in Bayer’s U.S. drug discovery and development portfolio. Our goal is to advance meaningful research around pathophysiology and discovery, working closely with Pitt to evaluate new therapeutic principles for heart, lung and blood diseases.”